NASDAQ:IVVD Invivyd (IVVD) Stock Price, News & Analysis $0.57 +0.03 (+4.79%) As of 02:15 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Invivyd Stock (NASDAQ:IVVD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Invivyd alerts:Sign Up Key Stats Today's Range$0.55▼$0.5850-Day Range$0.54▼$1.2252-Week Range$0.48▼$3.07Volume1.28 million shsAverage Volume3.58 million shsMarket Capitalization$167.63 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingHold Company Overview Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts. Read More Invivyd Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreIVVD MarketRank™: Invivyd scored higher than 57% of companies evaluated by MarketBeat, and ranked 417th out of 832 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingInvivyd has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialInvivyd has a consensus price target of $8.00, representing about 1,308.5% upside from its current price of $0.57.Amount of Analyst CoverageInvivyd has only been the subject of 3 research reports in the past 90 days.Read more about Invivyd's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Invivyd are expected to grow in the coming year, from ($0.50) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invivyd is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invivyd is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvivyd has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Invivyd's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.34% of the float of Invivyd has been sold short.Short Interest Ratio / Days to CoverInvivyd has a short interest ratio ("days to cover") of 8.56.Change versus previous monthShort interest in Invivyd has recently increased by 6.82%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInvivyd does not currently pay a dividend.Dividend GrowthInvivyd does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.94 News SentimentInvivyd has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Invivyd this week, compared to 5 articles on an average week.Search Interest9 people have searched for IVVD on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows5 people have added Invivyd to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Invivyd insiders have not sold or bought any company stock.Percentage Held by Insiders12.25% of the stock of Invivyd is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.36% of the stock of Invivyd is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Invivyd's insider trading history. Receive IVVD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IVVD Stock News HeadlinesInvivyd Receives Nasdaq Notice for Bid Price DeficiencyJuly 24, 2026 | tipranks.comInvivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDAJuly 6, 2026 | markets.businessinsider.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.July 30 at 1:00 AM | Paradigm Press (Ad)IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA ApprovalJuly 6, 2026 | finance.yahoo.comInvivyd, Inc. Announces FDA Notice of Termination for PEMGARDA EUA Following HHS COVID-19 Emergency Declaration Wind-DownJuly 6, 2026 | quiverquant.comQInvivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDAJuly 6, 2026 | globenewswire.comInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 | globenewswire.comNovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive OfficerJune 29, 2026 | globenewswire.comSee More Headlines IVVD Stock Analysis - Frequently Asked Questions How have IVVD shares performed this year? Invivyd's stock was trading at $2.47 at the beginning of the year. Since then, IVVD stock has decreased by 77.0% and is now trading at $0.5680. How were Invivyd's earnings last quarter? Invivyd, Inc. (NASDAQ:IVVD) released its quarterly earnings data on Thursday, May, 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.05. The company earned $13.74 million during the quarter, compared to analysts' expectations of $18.04 million. Invivyd had a negative trailing twelve-month return on equity of 53.48% and a negative net margin of 138.90%. Read the conference call transcript. When did Invivyd IPO? Invivyd (IVVD) raised $309 million in an initial public offering on Friday, August 6th 2021. The company issued 18,200,000 shares at a price of $16.00-$18.00 per share. How do I buy shares of Invivyd? Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Invivyd own? Based on aggregate information from My MarketBeat watchlists, some other companies that Invivyd investors own include American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/14/2026Today7/30/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 IVVD's financial health is in the Yellow zone, according to TradeSmith. IVVD has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IVVD CIK1832038 Webadagiotx.com Phone781-819-0080FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Price Target for Invivyd$8.00 High Price Target$10.00 Low Price Target$2.00 Potential Upside/Downside+1,306.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$52.49 million Net Margins-138.90% Pretax Margin-138.90% Return on Equity-53.48% Return on Assets-41.56% Debt Debt-to-Equity RatioN/A Current Ratio6.47 Quick Ratio6.47 Sales & Book Value Annual Sales$53.43 million Price / Sales3.14 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book0.55Miscellaneous Outstanding Shares294,610,000Free Float258,518,000Market Cap$167.63 million OptionableOptionable Beta0.67 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:IVVD) was last updated on 7/30/2026 by MarketBeat.com Staff. From Our PartnersCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThis Quiet Metals Story Is Starting To Stack UpA small North American mining company just hit 57-for-57 on exploration drilling—and that's only part of the s...i2i Marketing Group, LLC | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredGet “backdoor access” BEFORE the next big IPOWall Street insiders always get first access to pre-IPO shares at the lowest prices, locking in gains before t...The Oxford Club | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | SponsoredSell SpaceX Now. Buy This Instead.Rob Spivey traveled to SpaceX's Starbase, Texas headquarters to uncover what Wall Street missed in the company...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
